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ABSTRACT
We report the results of reduced-intensity unrelated cord blood transplantation (RI-UCBT) in patients with
advanced malignant lymphoma. Twenty patients (median age, 46.5 years; range, 27-66 years) underwent
RI-UCBT with a preparative regimen consisting of fludarabine 125 mg/m2, melphalan 80 mg/m2, and 4 Gy of
total body irradiation. The median infused total cell dose was 2.75  107/kg (range, 2.3-3.4  107/kg).
Graft-versus-host disease (GVHD) prophylaxis was composed of cyclosporine or tacrolimus alone. Fifteen
patients achieved primary neutrophil engraftment after a median of 20 days. Eight patients developed grade II
to IV acute GVHD, and 2 developed chronic GVHD. Of the 16 patients with evaluable disease, 10 achieved a
complete response. Primary disease recurred in 1 patient, and transplant-related mortality within 100 days
occurred in 8 of 20 patients. The estimated 1-year probability of progression-free survival was 50%. These data
suggest that RI-UCBT is a feasible option for patients with refractory lymphoma who lack an HLA-matched
donor.
© 2005 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Allogeneic stem cell transplantation is a curative
reatment for advanced or chemorefractory malig-
ant lymphoma [1,2]. The therapeutic beneﬁts are
ttributable to myeloablative radiochemotherapy and
he graft-versus-malignancy effect [3], whereas se-
ere regimen-related toxicity limits the efﬁcacy of
llogeneic hematopoietic stem cell transplantation
o young patients without comorbidities. Reduced-
ntensity stem-cell transplantation (RIST) with a
onmyeloablative preparative regimen has been de-
eloped to decrease regimen-related toxicity while r
14reserving an adequate antitumor effect. RIST may
e a curative treatment for heavily pretreated elderly
atients with malignant lymphoma [1,4-9]. Umbilical
ord blood from unrelated donors has been used as an
lternative stem cell source [10-13], and there have
een a few reported cases of cord blood transplanta-
ion for refractory lymphoma [8,14-18]. However, the
esults in adult lymphoma patients of treatment with
educed-intensity unrelated cord blood transplanta-
ion (RI-UCBT) remain unclear. We analyzed the
utcome of RI-UCBT in patients with relapsed or
efractory lymphoma.
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RI-UCBT for Patients with Refractory Lymphoma
BETHODS
Between September 2002 and April 2004, 20 adult
atients with refractory lymphoma were treated with
I-UCBT at Toranomon Hospital, Japan. Biopsy-
onﬁrmed histologic diagnosis was based on the syn-
nyms in the World Health Organization classiﬁca-
ion [19]. Of the 17 non-Hodgkin lymphoma patients,
had indolent lymphoma, and the other 15 had ag-
ressive lymphoma (Table 1). Eligible patients had
isease refractory to primary chemotherapy, had re-
apsed after ﬁrst-line conventional chemotherapy or
utologous transplantation, were considered inappro-
riate for conventional allogeneic hematopoietic stem
ell transplantation because of the lack of an HLA-
dentical sibling or a suitable unrelated donor, were
50 years old, and/or had organ dysfunction. Those
ith chemosensitive diseases included all patients who
ad shown a response to the last therapy before trans-
lantation (partial remission [PR] and complete remis-
ion [CR]); all other patients were classiﬁed as having
hemoresistant diseases growing through multiple che-
otherapy regimens (disease progression [PD]). All of
he patients provided written informed consent in
ccordance with the requirements of the institutional
eview board. Data analysis was performed on Decem-
er 1, 2004. The preparative regimen was composed
f ﬂudarabine 25 mg/m2 daily for 5 days, melphalan
0 mg/m2 daily for 1 day, and 4 Gy of total body
rradiation in 2 fractions for 1 day. Graft-versus-host
able 1. Patient Characteristics
Patient
No.
Age
(y)/Sex Histology Stage
Previous
Regimens/Previous
Auto-HSCT
1 27/M ALCL IV 6/No
2 32/F DLBCL IV 1/No
3 33/M DLBCL IV 3/No
4 40/M DLBCL III 6/No
5 40/M PTCL IV 1/No
6 41/F DLBCL IV 3/No
7 45/M DLBCL III 4/Yes (once )
8 46/F FL IV 1/No
9 47/M Nasal NK/T II 1/yes (once )
10 48/M DLBCL IV 2/No
11 48/F FL IV 5/No
12 52/F DLBCL IV 3/No
13 55/M DLBCL III 4/No
14 57/M DLBCL III 1/No
15 57/F DLBCL IV 4/Yes (once )
16 59/M DLBCL IV 3/Yes (once )
17 66/F IVL IV 2/No
18 28/F NS IV 5/Yes (twice)
19 32/F NS IV 3/No
20 47/M NS III 7/Yes (once )
LCL indicates anaplastic large-cell lymphoma; auto, autologous; C
lymphoma; FK, tacrolimus; FL, follicular lymphoma; HSCT,
lymphoma; Nasal NK/T, extranodal natural killer/T-cell lymp
progression of disease; PR, partial remission; SCT, stem cell trisease (GVHD) prophylaxis consisted of cyclosporin s
B&MT3 mg/kg alone (n  13) or tacrolimus 0.03 mg/kg
lone (n  7) from day 1 until the patients tolerated
ral administration. The dose was tapered off from
ay 100 until 150. Patients were treated in laminar
irﬂow rooms. All patients received prophylaxis with
ulfamethoxazole or sulfadoxine against Pneumocystis
arinii infection. Acyclovir and ﬂuconazole prophylaxis
ere routinely used. Red blood cell and platelet transfu-
ions were given to maintain hemoglobin levels8 g/dL
nd platelet counts 10  109/L. Blood products
ere irradiated. Neutropenic patients received broad-
pectrum intravenous antibiotics for the management
f febrile neutropenia. Filgrastim 5 g/kg/d was ad-
inistered subcutaneously from day1 until the neu-
rophil count was at least 1000/L for 3 consecutive
ays. The cord blood unit was selected according to
he number of nucleated cells per recipient’s weight
nd HLA compatibility (HLA-A and -B by serology
nd HLA-DRB1 by high-resolution DNA typing).
he chimerism status after RI-UCBT was determined
y ﬂuorescence in situ hybridization with a Y chromo-
ome probe for sex-mismatched RI-UCBT or by poly-
erase chain reaction DNA typing of HLA antigens for
LA-mismatched RI-UCBT. Graft failure was deﬁned
s peripheral cytopenia and marrow hypoplasia occur-
ing later than day 30, without detection of donor
arkers by cytogenetic or molecular techniques. The
robability of overall and progression-free survival
as estimated by the Kaplan-Meier method. Re-
vious
therapy
Remission
Status at
RI-UCBT
Cord Blood
Cell Dose
( 107/kg)
HLA
Disparities
GVHD
Prophylaxis
o CR2 2.39 4/6 FK
o CRI 2.71 4/6 CSP
es PD 2.78 4/6 CSP
es PD 2.27 4/6 FK
o PR 3.4 4/6 CSP
o PD 3.2 4/6 FK
es PD 2.56 4/6 CSP
o CR2 2.83 4/6 CSP
es PD 3 4/6 CSP
o PD 3.28 4/6 FK
o PD 2.71 4/6 CSP
o PD 2.81 4/6 FK
es PD 2.56 4/6 CSP
o PD 2.9 4/6 CSP
es PD 2.59 6/6 CSP
es PD 2.26 4/6 FK
o PD 2.69 4/6 CSP
o CR3 3.28 4/6 CSP
es PD 2.83 4/6 FK
es PD 2.34 4/6 CSP
plete remission; CSP, cyclosporine; DLBCL, diffuse large B-cell
poietic stem cell transplantation; IVL, intravascular large B-cell
nasal type; NS, nodular sclerosis classic Hodgkin lymphoma; PD,
tation; PTCL, peripheral T-cell lymphoma, unspeciﬁed.Pre
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3he recommendations of the international working
roup [20].
ESULTS
The characteristics of the 20 patients and cord
lood units are shown in Table 1. Nineteen (95%) of
he 20 patients had advanced-stage disease at diagnosis
stage III/IV) and an International Prognostic Index
core 2. Fifteen (75%) patients had refractory dis-
ase. Six patients (30%) had already experienced a
reatment failure with front-line autologous trans-
lantation. The median age of the patients was 46.5
ears (range, 27-66 years), the median weight was
6 kg (range, 44-75 kg), and the median number of
ryopreserved nucleated cells was 2.75  107/kg
range, 2.27-3.40  107/kg). Fifteen (75%) patients
ho underwent transplantation had a sustained en-
raftment as deﬁned by neutrophil counts 0.5 
09/L and an untransfused platelet count 20 
09/L for at least 3 consecutive days (Table 2). Pri-
ary graft failure occurred in 1 patient, and autolo-
ous recovery was not observed. The median time to
ecovery to an absolute neutrophil count of 0.5 
09/L was 20 days (range, 12-33 days), and the median
ime to achieve platelets 20  109/L was 39 days
range, 26-72 days). All patients with neutrophil en-
able 2. Outcomes
Patient
No.
Neutrophils
>5  108/L, d
Platelets
>20  109/L, d
Acute GVHD G
(Organ Involvem
and Stage)
1 20 34 0
2 20 35 0
3 NE NE NE
4 17 36 III (skin 2, liver 0,
5 16 40 0
6 NE NE NE
7 14 36 III (skin 2, liver 0,
8 23 72 III (skin 2, liver 0,
9 NE NE NE
10 23 39 0
11 33 NE IV (skin 3, liver 3,
12 22 NE 0
13 GF GF NE
14 NE NE NE
15 12 26 0
16 18 29 II (skin 3, liver 0, g
17 14 57 III (skin 3, liver 0,
18 13 43 I (skin 1, liver 0, g
19 25 48 III (skin 1, liver 0,
20 24 40 III (skin 0, liver 0,
R indicates complete remission; GF, graft failure; GVHD, gr
relapse.raftment showed full donor chimerism. Grade II to v
16V acute GVHD occurred in 8 of 15 evaluable pa-
ients, and chronic GVHD occurred in 2 of 11 evalu-
ble patients. As for disease response, both patients
ith indolent lymphoma, 8 of 15 patients with aggres-
ive lymphoma, and all 3 patients with Hodgkin lym-
homa achieved CR after transplantation. A total of
6 patients had measurable disease at transplantation,
nd disease was reassessed at regular intervals after
ransplantation. The maximal response was CR in 10
atients and PR in 1. Among the CR patients, the
edian time to CR was 88 days (range, 32-220 days).
hree of 4 patients in CR at RI-UCBT remain in
ustained remission, and 1 has died of PD. One
atient in PR at RI-UCBT achieved CR. Five of the
5 patients in PD at RI-UCBT achieved CR, 1
chieved PR, and 9 died of nonrelapse causes (sep-
is/pneumonia, n  7; acute GVHD, n  1; pul-
onary bleeding, n  1). The cumulative incidence
f nonrelapse mortality at 100 days was 41% (95%
onﬁdence interval, 19%-63%). At a median fol-
ow-up of 334.5 days (range, 213-482 days), 10 of
he 20 patients were alive: 9 in CR and 1 in PR. The
stimated 1-year overall and progression-free sur-
ival rates were both 50% (95% conﬁdence interval,
8%-72%; Figure 1). Total nucleated cell dose
LA disparities, disease status, and preceding ther-
pies were not associated with differences in sur-
Chronic GVHD (Organ
Involvement and Type)
Status post
RI-UCBT (d) Cause of Death
None CR, 242
NE Dead, 50, RL Disease
Progression
NE Dead, 15, NE Pulmonary
bleeding
None PR, 292
Extensive (skin, lung,
de novo)
CR, 352
NE Dead, 10, NE Sepsis
None CR, 471
None CR, 482
NE Dead, 18, NE Sepsis
None CR, 306
NE Dead, 74, CR Sepsis
NE Dead, 40, CR CMV
pneumonia
NE Dead, 44, NE Sepsis
NE Dead, 22, NE Sepsis
None CR, 392
None CR, 213
NE Dead, 73, CR GVHD
None CR, 406
Extensive (skin, gut,
quiessent)
CR, 317
None Dead, 113, CR Pneumonia
us-host disease; NE, not evaluable; PR, partial remission; RL,rade
ent
gut 2)
gut 0)
gut 0)
gut 3)
ut 0)
gut 3)
ut 0)
gut 2)
gut 2)
aft-versival (data not shown).
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RI-UCBT for Patients with Refractory Lymphoma
BISCUSSION
The results of our trial of RI-UCBT in patients
ith lymphoma whose disease recurred after a previ-
us treatment are encouraging. The rapid availability
f a unit of cord blood may be a particular advantage
or lymphoma patients who require urgent transplan-
ation, and cord blood can be an acceptable alternative
tem cell source. Our patients were heavily pretreated
nd included chemoresistant and aggressive histologic
ypes of disease whose outcome after RIST is reported
o be very poor, with median survival rates from 19%
o 32% at 1 year [21]. Despite our low-intensity con-
itioning regimen, a high rate of clinical remission
as observed. This suggests that RI-UCBT does exert
strong allogeneic graft-versus-lymphoma effect. The
edian of 100 days between RI-UCBT and the ap-
earance of a maximal response might be consistent
ith the time required for the activation and expan-
ion of antitumor cytotoxic T cells.
The transplant-related mortality of 41% at day
00 in this study was higher than that reported for
IST in other studies [11,13,21-23]. Patient age, prior
epeated therapies, disease status [24], and prolonged
mmunosuppression [25] would have played a role in
he high transplant-related mortality after RI-UCBT.
he proportion of deaths related to infection has
ecently been reported to be higher soon after cord
lood transplantation than after bone marrow trans-
lantation [12]. Additional strategies to promote en-
raftment and prevent early infectious complications
hould be developed, and this treatment strategy
hould be investigated among patients with less ad-
anced diseases.
In conclusion, although our patient cohort was
mall and the observation period was limited, our
esult suggests that RI-UCBT is feasible for patients
ith refractory lymphoma who lack a suitable donor
igure 1. Overall survival (OS) and progression-free survival (PFS)
fter transplantation. The estimated 1-year OS and PFS were both
0.0% (95% CI, 28.1%-71.9%).nd require urgent treatment. RI-UCBT is associated
B&MTith high transplant-related mortality, and this provides
rationale for a clinical study, which should be modiﬁed
o focus on minimizing toxicities, controlling infectious
omplications, and enhancing any graft-versus-leukemia
ffect.
CKNOWLEDGMENTS
We are indebted to the medical and nursing staff
f the Department of Hematology at the Toranomon
ospital for taking care of the patients and to the
hushikoku CBB, Kanagawa CBB, Hokkaido CBB,
yogo CBB, Metro Tokyo Red Cross CBB, Tokai
BB, Tokai University CBB (Cord Blood Bank), and
okyo CBB for processing the cord blood units. This
tudy was supported by a grant-in-aid of the Ministry
f Health, Labor and Welfare, Japan.
EFERENCES
1. Chopra R, Goldstone AH, Pearce R, et al. Autologous versus
allogeneic bone marrow transplantation for non-Hodgkin’s
lymphoma: a case-controlled analysis of the European Bone
Marrow Transplant Group Registry data. J Clin Oncol. 1992;
10:1690-1695.
2. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ,
Nieuwenhuis HK. Allogeneic versus autologous bone marrow
transplantation for refractory and recurrent low-grade non-
Hodgkin’s lymphoma. Blood. 1997;90:4201-4205.
3. Khouri IF, Keating M, Korbling M, et al. Transplant-lite:
induction of graft-versus-malignancy using ﬂudarabine-based
nonablative chemotherapy and allogeneic blood progenitor-cell
transplantation as treatment for lymphoid malignancies. J Clin
Oncol. 1998;16:2817-2824.
4. Goldstone AH, Kottaridis PD. The allogeneic effect in non-
Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S91-
S97.
5. Branson K, Chopra R, Kottaridis PD, et al. Role of nonmy-
eloablative allogeneic stem-cell transplantation after failure of
autologous transplantation in patients with lymphoproliferative
malignancies. J Clin Oncol. 2002;20:4022-4031.
6. Tanimoto TE, Kusumi E, Hamaki T, et al. High complete
response rate after allogeneic hematopoietic stem cell trans-
plantation with reduced-intensity conditioning regimens in ad-
vanced malignant lymphoma. Bone Marrow Transplant. 2003;32:
131-137.
7. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic
hematopoietic transplantation as adoptive immunotherapy for
indolent lymphoma: low incidence of toxicity, acute graft-ver-
sus-host disease, and treatment-related mortality. Blood. 2001;
98:3595-3599.
8. Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C,
Prince HM. Graft-versus-lymphoma effect in refractory cuta-
neous T-cell lymphoma after reduced-intensity HLA-matched
sibling allogeneic stem cell transplantation. Bone Marrow Trans-
plant. 2004;34:521-525.
9. Dhedin N, Giraudier S, Gaulard P, et al. Allogeneic bone
marrow transplantation in aggressive non-Hodgkin’s lym-
phoma (excluding Burkitt and lymphoblastic lymphoma): a se-
317
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
K. Yuji et al.
3ries of 73 patients from the SFGM database. Societ Francaise de
Greffe de Moelle. Br J Haematol. 1999;107:154-161.
0. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic en-
graftment and survival in adult recipients of umbilical-cord
blood from unrelated donors. N Engl J Med. 2001;344:1815-
1822.
1. Miyakoshi S, Yuji K, Kami M, et al. Successful engraftment
after reduced-intensity umbilical cord blood transplantation for
adult patients with advanced hematological diseases. Clin Cancer
Res. 2004;10:3586-3592.
2. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after
transplantation of cord blood or bone marrow from unrelated
donors in adults with leukemia. N Engl J Med. 2004;351:2265-
2275.
3. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS,
Wagner JE. Rapid and complete donor chimerism in adult
recipients of unrelated donor umbilical cord blood transplan-
tation after reduced-intensity conditioning. Blood. 2003;102:
1915-1919.
4. Rizzieri DA, Long GD, Vredenburgh JJ, et al. Successful allo-
geneic engraftment of mismatched unrelated cord blood fol-
lowing a nonmyeloablative preparative regimen. Blood. 2001;98:
3486-3488.
5. Weinthal JA, Goldman SC, Lenarsky C. Successful treatment
of relapsed Burkitt’s lymphoma using unrelated cord blood
transplantation as consolidation therapy. Bone Marrow Trans-
plant. 2000;25:1311-1313.
6. Ooi J, Iseki T, Ito K, et al. Successful unrelated cord blood
transplantation for relapse after autologous transplantation in
non-Hodgkin’s lymphoma. Leuk Lymphoma. 2002;43:653-655.7. Yoshimasu T, Manabe A, Tanaka R, et al. Successful treatment of
18relapsed blastic natural killer cell lymphoma with unrelated cord
blood transplantation. Bone Marrow Transplant. 2002;30:41-44.
8. Chao NJ, Koh LP, Long GD, et al. Adult recipients of umbil-
ical cord blood transplants after nonmyeloablative preparative
regimens. Biol Blood Marrow Transplant. 2004;10:569-575.
9. Pathlogy and Genetics. Tumors of Hematopoietic and Lymphoid
Tissues. Geneva: World Health Organization; 2001.
0. Cheson BD, Horning SJ, Coifﬁer B, et al. Report of an inter-
national workshop to standardize response criteria for non-
Hodgkin’s lymphomas. NCI Sponsored International Working
Group. J Clin Oncol. 1999;17:1244.
1. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemore-
sistant or aggressive lymphoma predicts for a poor outcome
following reduced-intensity allogeneic progenitor cell trans-
plantation: an analysis from the Lymphoma Working Party of
the European Group for Blood and Bone Marrow Transplan-
tation. Blood. 2002;100:4310-4316.
2. Toze CL, Barnett MJ, Connors JM, et al. Long-term disease-
free survival of patients with advanced follicular lymphoma
after allogeneic bone marrow transplantation. Br J Haematol.
2004;127:311-321.
3. Escalon MP, Champlin RE, Saliba RM, et al. Nonmyeloabla-
tive allogeneic hematopoietic transplantation: a promising sal-
vage therapy for patients with non-Hodgkin’s lymphoma whose
disease has failed a prior autologous transplantation. J Clin
Oncol. 2004;22:2419-2423.
4. Long GD, Laughlin M, Madan B, et al. Unrelated umbilical
cord blood transplantation in adult patients. Biol Blood Marrow
Transplant. 2003;9:772-780.
5. Klein AK, Patel DD, GoodingME, et al. T-cell recovery in adults
and children following umbilical cord blood transplantation. Biol
Blood Marrow Transplant. 2001;7:454-466.Erratum
In the March issue of BBMT the article by Drs. Lamb and Lopez (T cells: a new frontier for immunotherapy?
Biol Blood Marrow Transplant. 2005;11:161-168) included an editing error. The phrase “guanosine mono-
phosphate” was inadvertently inserted in place of “good manufacturing product”. The correct passage is as
follows: “Techniques are currently being developed for good manufacturing product–compatible clinical
scale ex vivo expansion of T cells. The first clinical trials are expected within the next 6 to 12 months.”
